Genprex reports positive updates from its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials in lung cancer, showing prolonged progression-free survival and partial remission in patients. The company is refocusing its oncology clinical development program and advancing work on biomarkers to enrich clinical trial patient populations.